logo
Test Your Psychological Safety At Work After Recent Mass Shootings

Test Your Psychological Safety At Work After Recent Mass Shootings

Forbes3 days ago
After a lone gunman killed four employees in Manhattan before fatally shooting himself this summer, the mass murders have renewed concerns about psychological safety at work. The deadliest gun attack in New York City in 25 years during rush hour in the corporate offices of the National Football League, along with workplace and church shootings, have renewed concerns about psychological safety at work. How safe do you feel at work? Test your workplace on five security criteria.
Types Of Psychological Safety At Work
Workplace psychological safety is the absence of fear while working, a prerequisite for job engagement and performance. Employees are not looking over their backs while engaged. They feel free to express their thoughts, have disagreements, voice opinions and give feedback without fear of reprisal.
Psychological safety fosters an environment where team members feel valued, respected and empowered to take risks or initiative without fear of rejection, humiliation or judgment. Psychological safety can be compromised when employees are constantly faced with uncertainty at work. Inevitable uncertainties instantly arouse fight-or-flight reactions.
Your survival brain is constantly updating your world, making judgments about what's safe and what isn't. The brain will do almost anything for the sake of certainty because we're hardwired to overestimate threats and underestimate our ability to handle them. Psychological safety at work is compromised in numerous instances. Test your workplace to see if any of the following conditions exist.
The Occupational Safety and Health Administration (OSHA) found that nearly two million U.S. workers are victims of workplace violence each year. Given the rise in ICE raids, mass shootings, cyber threats and other acts of workplace violence, emergency plans are not always in place. And if they are, employees are often unaware of them.
Verkada and The Harris Poll just released the Healthcare Worker Safety Report, revealing more than 80% of healthcare workers want their employers to increase security measures amid increased violence and harassment. Two in five have considered leaving their jobs due to safety concerns–many planning to leave within a year.
The report shows that healthcare workers face a disproportionately high risk of workplace violence, accounting for 73% of all nonfatal workplace injuries and illnesses due to violence. They are four times more likely to suffer from workplace violence than workers in other settings, according to Bureau of Labor Statistics.
Increasing widespread episodes of violence, threats and aggressive behaviors are taking a toll on nurses, doctors and medical staff, according to the study. It also reveals that workplace violence is among the primary drivers pushing them to pursue work outside of the industry.
A body of research has linked sexual harassment in the workplace to mental health factors such as psychological distress, anxiety and depression and physical health issues such as illnesses and absenteeism due to poor health.
Workers exposed to sexual harassment are at greater risk of suicide and attempting suicide. Experts consider workplace sexual harassment as an occupational hazard and a significant public health problem, urging that new ways to prevent and address workplace sexual harassment are needed. They also advise that survivors of sexual harassment receive mental health screening and treatment to mitigate risks for subsequent mental health concerns and suicidal leanings.
Massive layoffs, skyrocketing prices and not knowing what the future holds in today's tightening economy can create layoff anxiety. When we don't have all the facts about uncertain layoffs, it's natural to jump to conclusions with made-up stories that trigger stress. Your company lays off a ton of employees, and you assume your neck is on the chopping block next.
The constant threat of being laid off can be deeply disturbing--even traumatic. An unexpected, sudden layoff can feel like you're blindsided by a truck. It can upend your security, confidence and career plans and significantly impact your mental health. A recent study shows that 37% of Americans say they're losing sleep over job security. A notable 64% lie awake thinking about money every week. And 56% have lost sleep over fears they won't be able to pay their bills.
"Quiet vacations' are workarounds, motivated mainly by employee fear. A Harris Poll found that 78% of workers (mostly Gen Z and Millennials) don't take all their PTO, because they're afraid of being judged as slackers.
In another study, 29% of employees cited layoff fears, making them hesitant to take time off this summer. After witnessing the approximately 1.6 million workers laid off or discharged in May 2025 alone and the 8.4 million layoffs and discharges occurring in 2025 so far, employees are afraid of losing their jobs if they visibly show they are prioritizing their well-being.
Dr. Marais Bester, senior consultant at SHL, argues that 'quiet vacations' are a call to action for employers. Employees need a break but don't feel safe enough to ask for one. He insists that workers are not sneaky. They don't feel safe or supported to take the leave they are contractually entitled to. So they "find workarounds, jiggling their mouse to stay 'active,' turning video off on calls, answering just enough emails to look busy.'
Dr. Mariel Paralitici-Morales, chief medical officer at Adult and pediatric Institute told me that many employees worry about facing negative consequences if they speak up or make mistakes, which puts a damper on open communication. She points out that this often happens in rigid hierarchies with top-heavy structures where employees feel intimidated to share their thoughts.
Morales says it's difficult to introduce new practices that encourage psychological safety when the company culture is resistant to change. She adds that, if leaders send mixed messages or behave unpredictably, it can make it hard for employees to feel safe and secure in expressing themselves, but psychological safety can be a game changer.
"When people feel safe to share their ideas, ask questions or even admit mistakes without worrying about being judged or punished, they tend to be more involved and creative,' Morales explains. 'This type of open environment really helps with teamwork, making it easier to solve problems and come up with new ideas, which in turn boosts the whole team's performance.'
She encourages open communication so people can give feedback, have real conversations and feel heard and valued. 'Leaders can make a big difference by showing vulnerability themselves, like admitting their mistakes and being open to feedback," she asserts.
A Final Word On Psychological Safety At Work
Gallup found that moving the needle on psychological safety can lead to reduction in turnover (27%), in safety incidents (40%) and increases in productivity (12%). It's the leader's responsibility to create psychological safety at work so all employees can thrive. 'In the long run, when you focus on creating a safe space, you end up with a more innovative and flexible culture,' Morales concludes. 'People feel motivated to do their best work, which boosts job satisfaction and keeps them around longer.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mom says infant may have rare tick-borne disease
Mom says infant may have rare tick-borne disease

Yahoo

time25 minutes ago

  • Yahoo

Mom says infant may have rare tick-borne disease

A Massachusetts mom says her infant daughter may be the patient that state health officials recently said is under investigation for contracting a rare tick-borne virus infection. "Public health officials are investigating preliminary results of a Powassan virus infection in a Martha's Vineyard resident," Barnstable County said in a press release Tuesday, without identifying the resident. Barnstable County, which comprises the 15 towns of Cape Cod and sits just north of Martha's Vineyard, said that according to data from the Centers for Disease Control and Prevention, there has been just one other known case of Powassan virus in the area in the last 20 years and only three total Powassan virus cases in Massachusetts this year. The CDC notes there are currently 24 reported Powassan cases nationwide. Tiffany Sisco, who declined to be interviewed by ABC News, told Boston ABC station WCVB that she found a tick on her 5-week-old daughter Lily Belle Sisco during an outdoor walk, and despite removing it, she noticed Lily developed symptoms a week later. "I found this tiny, tiny, tiny [tick], the teeniest one on her ankle," Sisco said. "I picked it off. A week later, she started getting a fever of 102 [degrees Fahrenheit]. I said, 'I'm taking her right in.'" What is the Powassan virus? Powassan virus is a disease or illness caused by the Powassan virus and is mostly spread by infected ticks that have the Powassan virus or deer tick virus, according to the CDC. The ticks may get infected when they feed on other animals that have the virus, such as groundhogs, mice, squirrels or other rodents. ER visits for tick bites near record levels this summer across US Although considered rare, the CDC notes that Powassan infections have been increasing in recent years, with most infections occurring in northeast states and the states around the Great Lakes region in the spring and fall, when ticks are most active. The Powassan virus can also be transmitted by blood, so anyone who has the virus should not donate blood or bone marrow for at least 120 days after infection. What are the symptoms of Powassan virus and how is it treated? Symptoms of Powassan virus include headache, fever, vomiting and weakness, according to the CDC. The virus can also cause severe disease, the agency states, including inflammation of the brain or inflammation of the membranes around the brain or spinal cord. Symptoms of a severe infection may include confusion, loss of coordination, trouble speaking, and seizures. Some people, such as children, older adults and people with weakened immune systems, may be at higher risk of developing severe symptoms. People with Powassan virus may require fluids, pain medications and rest to alleviate symptoms, but anyone with severe disease may need to be admitted to a hospital for further treatment. What to know about tick-borne illnesses How to prevent tick-borne illnesses There are currently no medications or vaccines to prevent a Powassan virus infection, according to the CDC. However, there are precautions you can take to protect you and your family from tick bites and any subsequent infections. These include: Applying EPA-registered insect repellents. Wearing long-sleeved clothing and pants. Avoiding bushy and wooded areas. Checking for ticks thoroughly and remove any after spending time outdoors. The CDC also advises treating outdoor clothing and gear with products containing 0.5% permethrin, an insect repellent, which will "remain protective through several washings." Solve the daily Crossword

More than 400 indirect deaths linked to LA wildfires, study suggests
More than 400 indirect deaths linked to LA wildfires, study suggests

Yahoo

time25 minutes ago

  • Yahoo

More than 400 indirect deaths linked to LA wildfires, study suggests

More than 400 additional deaths are estimated to be linked to the wildfires that ravaged Los Angeles earlier this year, according to a new study. The figure, published on Wednesday in the medical journal JAMA, looks at deaths that have been attributed to factors caused by the wildfires, like poor air quality and delays in accessing healthcare. It is a higher figure than the official death count of 31 by the Los Angeles County, which tallied deaths caused directly by the fires. The study comes as hundreds of wildfires burn across the US and Canada, prompting air quality advisories in cities like Chicago, Buffalo and New York. The Palisades and Eaton fires tore through Los Angeles in January, destroying thousands of structures and leading to the evacuation of more than 100,000 Los Angeles residents. Why wildfires are becoming faster and more furious The far-reaching impacts of wildfire smoke – and how to protect yourself The latest study revealed that around 440 people are estimated to have died as a result of the wildfires between 5 January and 1 February. Researchers said they tallied the figure by looking at all deaths and their causes in Los Angeles during the period of the fires, and comparing it to similar data from previous years. The results show that there were nearly 7% more deaths during the wildfires. Some are attributed to lung and heart conditions exacerbated by smoke or stress, while others are more indirect - like delayed healthcare treatment for dialysis or cancer patients as a result of fire-related disruptions. The authors said that the findings underscore the need for officials to count both direct and indirect fatalities of wildfires and other climate-related emergencies when trying to quantify their impact. "They also highlight the need for improved mortality surveillance during and after wildfire emergencies," the authors said, noting that their figures are provisional as there may have been additional fire-related deaths beyond the scope of the study. The BBC has reached out to Los Angeles County officials for comment on the study's findings. Another study released on Wednesday in JAMA that looked at the aftermath of the 2023 Maui wildfires showed that 22% of adults in the region had reduced lung function, and half displayed symptoms of depression. The fires, which broke out in August 2023 and were the worst to affect Hawaii in recent history, killed at least 102 people and destroyed more than 2,000 structures. The authors of the Maui study said their results show the need for "sustained clinical monitoring and community-based mental health supports" months after a climate disaster. A second study on the Hawaii fires suggests that Maui saw the highest suicide and drug overdose rates in the month of the 2023 wildfires. Wildfires have become more frequent in recent years as a result of climate change, driven by hotter and drier weather that fuels fire spread. In addition to directly threatening lives and structures, smoke from wildfires has been shown to have adverse health effects on people. Wildfire smoke has been found to be harmful to certain immune cells in the lungs, with a toxicity four times greater than particulates from other types of pollution. This can have a long-term impact on cardiovascular health, experts have said. Older people, pregnant women and young children, as well as those with underlying health conditions, such as heart disease or asthma, are more likely to get sick, experts say. But the smoke can also impact healthy adults. One dead and thousands evacuated as wildfire spreads in France Massive clouds of smoke blanket parts of California as Gifford fire grows Canadian wildfires prompt New York air quality alert Ten workers killed battling wildfires in Turkey

Senseonics Holdings, Inc. Reports Second Quarter Financial Results
Senseonics Holdings, Inc. Reports Second Quarter Financial Results

Yahoo

time25 minutes ago

  • Yahoo

Senseonics Holdings, Inc. Reports Second Quarter Financial Results

Generated Q2 revenue of $6.6 million, representing year-over-year growth of 37% Achieved a 79% increase in U.S. new patient starts over prior year GERMANTOWN, Md., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the second quarter ended June 30, 2025. Recent Highlights & Accomplishments: Generated revenue of $6.6 million in the second quarter of 2025, an increase of 37% versus the second quarter of 2024, driven by 79% new patient growth in the U.S. over prior year Expanded direct-to-consumer (DTC) advertising campaign to drive further awareness and adoption of Eversense in the U.S., with the first month of enhanced campaign generating a 50% increase in leads over prior three-month average Completed transition of providers to Eon Care from the Nurse Practitioner Group (NPG), now with 38 providers to support patient access to insertions CMS updated the Medicare Physician Fee Schedule, providing reimbursement for a full year of usage with Eversense 365 as a medical benefit Entered into a commercial development agreement to integrate Sequel Med Tech's twiist™ automated insulin delivery (AID) system with Eversense 365, with launch expected in Q4 Raised $77.8 million in total gross proceeds, including $57.5 million in a public offering and $20.3 million from Abbott in a concurrent private placement, to fund the ongoing launch of Eversense 365 and continued development of pipeline products 'During the quarter we continued to drive a strong U.S. Eversense 365 launch focused on new patients, initiating enhanced DTC advertising in June to broaden actionable leads and enable acceleration in patients and revenue growth in the second half of the year,' said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. 'We advanced several other important strategic initiatives which drive uptake and advance our technology to position us for increased shareholder value while progressing the development of Gemini and Freedom.' Second Quarter 2025 Results:Total revenue for the second quarter of 2025 was $6.6 million compared to $4.9 million for the second quarter of 2024. U.S. revenue was $4.9 million for the second quarter of 2025 compared to $3.0 million for the second quarter of 2024, and revenue outside the U.S. was $1.7 million in the second quarter of 2025 compared to $1.9 million in the prior year period. Second quarter 2025 gross profit of $3.1 million compared to gross profit of $0.3 million for the second quarter of 2024. The increase in gross profit was primarily driven by increased margins on the 365-day product and a one-time gain as the result of previously expensed value-added tax recovered from prior years. Second quarter 2025 research and development expenses decreased by $3.1 million year-over-year, to $7.7 million (from $10.8 million). The decrease was primarily due to a reduction in clinical studies spend and consultant costs due to the completion of 365-day product trials. Second quarter 2025 selling, general and administrative expenses increased by $0.7 million year-over-year, to $9.7 million (from $9.0 million). The increase was primarily driven by higher sales commissions expenses due to an increase in consignment sales and an increase in personnel costs to support the Eon Care inserter network. Net loss was $14.5 million, or a $0.02 loss per share, in the second quarter of 2025 compared to net loss of $20.3 million, or a $0.03 loss per share, in the second quarter of 2024. Net loss decreased by $5.8 million primarily due to improved gross profit margins of Eversense 365 sales in the United States and the overall reduction in research and development costs. Full Year 2025 Financial OutlookSenseonics continues to expect full-year 2025 global net revenue to be approximately $34-38 million as we continue to roll out Eversense 365 to U.S. patients. The full-year 2025 financial outlook assumes approximately doubling of our global patient base during 2025, with approximately one-third of revenue generated in the first half of 2025 and two-thirds of revenue to be generated in the second half of 2025, second half revenue will be weighted to the fourth quarter due to once-a-year Eversense 365 reorder dynamics following its Q4 launch. The financial outlook takes into consideration current assumptions regarding: (i) refined visibility of the timeline and specifications for the regulatory approval and the plans for commercial transition to Eversense 365 outside the United States, (ii) projected plans with respect to spending on the DTC marketing campaign to generate additional leads, (iii) executing on other sales and marketing initiatives, (iv) anticipated utilization and impact of the patient assistance programs for Eversense 365, and (v) continued progress with the transition of reimbursement from Eversense E3 to Eversense 365. Gross margins are expected to increase throughout 2025, with 2025 gross margins between 32.5% and 37.5% for the full year. Cash used in operations in 2025 is expected to be approximately $60 million. Conference Call and Webcast Information:Company management will host a conference call at 4:30 pm (Eastern Time) today, August 6, 2025, to discuss these financial results and recent business developments. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at this link. Individuals interested in participating in the call via telephone may access the call by dialing +1-800-225-9448 (+1-203-518-9708 for those outside the U.S. or Canada) and referencing Conference ID SENSQ2. A replay of the call can be accessed on Senseonics' website under 'Investor Relations.' About SenseonicsSenseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone. About EversenseThe Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see About Ascensia Diabetes CareAscensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives. We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity. Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries. For further information, please visit the Ascensia Diabetes Care website at: About PHC Holdings CorporationPHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience Corporation, Mediford Corporation, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2024 were JPY 353.9 billion with global distribution of products and services in more than 125 countries. ©2025 Ascensia Diabetes Care Holdings AG. All right reserved. Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. Forward Looking StatementsAny statements in this press release about future expectations, plans and prospects for Senseonics, including the revenue, gross margin, cash flow and global installed customer base projections, and global installed customer base and reorder assumptions, under the heading 'Full Year 2025 Financial Outlook,' statements regarding plans, timing and success of the commercial launch of the 365-day system and the adoption of, access to, or growth of use of Eversense, statements regarding future demand for Eversense, statements regarding development programs and next generation systems, statements regarding the collaboration with Sequel and the anticipated timing for commercial availability of an integrated twiistTM AID system with Eversense 365, the future regulatory approval and the potential to commercially launch Eversense 365 outside the U.S., and other statements containing the words "believe," 'expect,' 'intend,' 'may,' 'projects,' 'will,' 'planned,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the reliance on and execution of Ascensia Diabetes Care, the Company's commercialization partner for Eversense, uncertainties with respect to any additional commercial support that will be required for successful commercialization of Eversense, and other commercial initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration and roll-out of new technology and solutions, uncertainties inherent in finalizing integration and commercial terms and coordination with health systems and other new collaboration partners and third parties, uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product and Senseonics' and its partners' activities, uncertainties relating to the current economic and regulatory/political environment, including the effects of tariffs, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024, the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 and future reports filed with the SEC under the heading "Risk Factors." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof. Senseonics Investor ContactJeremy FefferLifeSci Advisorsinvestors@ Senseonics Holdings, Consolidated Balance Sheets(in thousands, except share and per share data) June 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 31,518 $ 74,597 Restricted cash 315 315 Short term investments, net 94,894 — Accounts receivable, net 2,853 1,365 Accounts receivable, net - related parties 2,304 4,921 Inventory, net 4,714 4,421 Prepaid expenses and other current assets 4,990 5,819 Total current assets 141,588 91,438 Deposits and other assets 4,729 4,926 Property, equipment and intangible assets, net 3,957 4,074 Total assets $ 150,274 $ 100,438 Liabilities and Stockholders' Equity (Deficit) Current liabilities: Accounts payable $ 2,269 $ 3,205 Accrued expenses and other current liabilities 9,883 13,636 Accrued expenses and other current liabilities, related parties 2,624 1,870 Notes payable, current portion, net — 20,138 Total current liabilities 14,776 38,849 Long-term debt and notes payables, net 35,230 34,703 Non-current operating lease liabilities 5,548 5,785 Total liabilities 55,554 79,337 Preferred stock and additional paid-in-capital, subject to possible redemption: $0.001 par value per share; 0 and 12,000 shares issued and outstanding as of June 30, 2025 and December 31, 2024 — 37,656 Total temporary equity — 37,656 Commitments and contingencies Stockholders' equity (deficit): Common stock, $0.001 par value per share; 1,400,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 814,576,132 shares and 595,351,210 shares issued and outstanding as of June 30, 2025 and December 31, 2024 815 595 Additional paid-in capital 1,070,516 930,724 Accumulated other comprehensive loss 23 — Accumulated deficit (976,634 ) (947,874 ) Total stockholders' equity (deficit) 94,720 (16,555 ) Total liabilities, temporary equity and stockholders' equity (deficit) $ 150,274 $ 100,438 Senseonics Holdings, Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share data) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenue, net $ 3,223 $ 778 $ 5,033 $ 1,367 Revenue, net - related parties 3,426 4,087 7,873 8,545 Total revenue 6,649 4,865 12,906 9,912 Cost of sales 3,528 4,567 8,280 9,279 Gross profit 3,121 298 4,626 633 Expenses: Research and development expenses 7,715 10,800 15,014 21,238 Selling, general and administrative expenses 9,729 8,991 17,423 17,119 Operating loss (14,323 ) (19,493 ) (27,811 ) (37,724 ) Other (expense) income, net: Interest income 973 1,190 1,648 2,574 Interest expense (1,145 ) (2,085 ) (2,574 ) (4,133 ) Gain on change in fair value of derivatives — 102 — 102 Other (expense) income (6 ) (1 ) (23 ) 17 Total other (expense) income, net (178 ) (794 ) (949 ) (1,440 ) Net Loss (14,501 ) (20,287 ) (28,760 ) (39,164 ) Other comprehensive loss Unrealized gain (loss) on marketable securities 26 (5 ) 23 4 Other comprehensive gain (loss) 26 (5 ) 23 4 Total comprehensive loss $ (14,475 ) $ (20,292 ) $ (28,737 ) $ (39,160 ) Basic net loss per common share $ (0.02 ) $ (0.03 ) $ (0.04 ) $ (0.06 ) Basic weighted-average shares outstanding 813,364,903 616,585,664 766,382,267 615,587,105 Diluted net loss per common share $ (0.02 ) $ (0.03 ) $ (0.04 ) $ (0.06 ) Diluted weighted-average shares outstanding 813,364,903 616,585,664 766,382,267 615,587,105

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store